WHO ICTRP trial
Ludwig
EUCTR2015-005298-19-GB · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2015-005298-19-GB |
|---|---|
| Public title | Ludwig |
| Scientific title | Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer - LUD2015-005 |
| Primary sponsor | Ludwig Institute for Cancer Research Ltd. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United Kingdom |
| Conditions | Oesophageal Cancer MedDRA version: 20.0 Level: LLT Classification code 10026180 Term: Malignant neoplasm of oesophagus System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: Durvalumab Product Code: MEDI4736 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Durvalumab Current Sponsor code: MEDI4736 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal… |
| Registration date | Jan 28, 2016 |
| Target size | 75 |
| Secondary IDs | LUD2015-005;NCT02735239 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: